CRA_1801

CRA_1801 is a synthetic small molecule belonging to the benzimidazole class of organic compounds. It has been identified as a potential inhibitor of leucine-rich repeat kinase 2 (LRRK2), an enzyme implicated in the pathogenesis of Parkinson’s disease. Computational modeling and virtual screening studies have suggested that CRA_1801 exhibits strong predicted binding affinity for LRRK2, with pIC50 values greater than 7, indicating potent inhibitory activity. The compound's mechanism involves direct inhibition of LRRK2 kinase activity, which may modulate neurodegenerative processes associated with Parkinson’s disease. As of now, there are no reports indicating clinical development or approval; its status remains investigational and preclinical[5][9][1].

Other names

CRA_18012-(3-hydroxypyridin-2-yl)-1H-benzimidazole-5-carboximidamide2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL–2-YL}PYRIDIN–3–OLATE